|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Asthma and COPD - Control is the Goal
Datamonitor, Oct 2004, Pages: 90
The world market for asthma/COPD drugs, valued at $13.3 billion in 2003, is forecast to grow to $19.0 billion by 2009, driven by the expansion of combination steroid/bronchodilator products into a wider spectrum of patients, and strong growth in COPD specific therapies.
GlaxoSmithKline and Merck remain the indisputable leaders in asthma, with Pfizer steadily building a presence in COPD.
Scope -
Outlook for the asthma/COPD market, including key events impacting combination products, leukotriene antagonists, and anticholinergics
Global sales forecasts to 2014, including country-specific forecasts for the US, Japan, France, Germany, Italy, Spain and the UK
Review of global and country specific opportunities and threats impacting key brands, including Seretide, Symbicort, Singulair, Spiriva, and Daxas
Case studies on Seretides promotional strategies on redefining asthma management, and building Xopenexs primary care presence
Highlights -
GSK has added fresh impetus to Seretide growth by focusing on the control of asthma, rather than symptom severity, enabling Seretide to appeal to the full spectrum of patients and move beyond moderate to severe asthma.
The growth of Spiriva and Daxas will add breadth to an underdeveloped market and establish Pfizer as the premier company in COPD, which is the fastest growing segment of the market. Landmark morbidity and mortality trials, improved awareness, diagnosis and earlier therapeutic intervention, indicates a very promising outlook for this disease.
The dominance of Seretide and Singulair is not likely to be challenged in the foreseeable future, although the large market size, with few NCEs, makes it possible for companies to successfully launch niche products through effective patient targeting.
Reasons to Purchase -
Evaluate the expansion of combination products into a wider spectrum of patients through new indications and promotional activities
Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds
Examine the impact of future patent expiries in each of the seven country markets
Customers who bought this item also bought
Commercial Insight: Asthma & COPD - On the verge of generic entry
Commercial Insight: Asthma & COPD - Combination products still have blockbuster potential
Asthma And COPD - Get Smart
Pipeline Insight: Asthma/COPD - Simplified Treatments to Split the Market
Forecast Insight: Asthma/COPD - Little Long-term Future for Long-acting Single-agent Inhalers?
Pipeline Insight: Asthma/COPD - Targeted Therapies on the Horizon
Commercial Insight: Asthma and Copd - Combinations breathe life into the asthma and Copd markets
Commercial Insight: Asthma/COPD - ICS/LABA Combinations Continue to Dominate
Asthma and COPD Market Forecast
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2011
Asthma & COPD Therapeutics
IMS Therapy Report: Asthma & COPD
|
|
|
|
